epirubicin has been researched along with Animal Mammary Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Bertheau, P; de Thé, H; El-Bouchtaoui, M; Ferreira, I; Grigoriu, C; Janin, A; Jeanne, M; Leboeuf, C; Lehmann-Che, J; Marangoni, E; Plassa, LF; Poupon, MF; Ratajczak, P; Turpin, E; Varna, M | 1 |
2 other study(ies) available for epirubicin and Animal Mammary Carcinoma
| Article | Year |
|---|---|
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cellular Senescence; Cyclophosphamide; DNA Mutational Analysis; DNA, Neoplasm; Epirubicin; Genes, p53; Humans; Mammary Neoplasms, Animal; Mice; Mutation; Neoplasm Transplantation; Tumor Suppressor Protein p53 | 2009 |